|
May 14
|
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
|
|
Mar 27
|
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
|
|
Dec 7
|
Kintara Therapeutics Announces Review of Strategic Alternatives
|
|
Dec 5
|
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
|
|
Sep 25
|
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
|
|
Aug 9
|
Kintara Therapeutics to Present at the Emerging Growth Conference
|
|
Aug 8
|
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
|